EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY 4.0

Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradication of Helicobacter pylori: a meta-analysis

Manning Li, Ying Xie

Frontiers in Cellular and Infection Microbiology · 12.02.2025 · 15

DOI: 10.3389/fcimb.2025.1441185 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 12.02.2025. Verfasst von Manning Li und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China. Hauptthemen laut MEDLINE: Helicobacter Infections, Helicobacter pylori, Probiotics, Saccharomyces boulardii. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Helicobacter pylori ( H. pylori ) is highly prevalent worldwide and is closely associated with many gastric conditions. Current methods for eradicating H. pylori include triple or quadruple therapy, including antibiotics, proton pump inhibitors, and bismuth agents; however, with antibiotic abuse and increased drug resistance rates, the effectiveness of traditional methods is gradually decreasing, with many adverse effects such as abdominal pain, diarrhea, and intolerance. In recent years, there has been controversy regarding whether adding Saccharomyces boulardii ( S. boulardii ) to traditional therapies is beneficial for eradicating H. pylori .

Aim

To evaluate the efficacy and safety of S. boulardii as an adjuvant therapy for the eradication of H. pylori .

Methods

We systematically searched the PubMed and Web of Science databases from January 2002 to January 2023. The primary outcome was the H. pylori eradication rate. The secondary outcomes included total adverse effects, abdominal pain, diarrhea, bloating, constipation, nausea, vomiting, taste disorders, and other adverse reactions. We evaluated the included studies for publication bias and heterogeneity. Fixed- and random-effects models were used for studies without and with heterogeneity, respectively, to calculate the risk ratios (RRs) and conduct sensitivity and subgroup analyses.

Results

Nineteen studies comprising 5,036 cases of H. pylori infection were included in this meta-analysis. The addition of S. boulardii to traditional therapy significantly improved the H. pylori eradication rate [RR=1.11, 95% confidence interval (CI): 1.08–1.15] and reduced the incidence of total adverse effects (RR=0.49, 95% CI: 0.37–0.66), diarrhea (RR=0.36, 95% CI: 0.26–0.48), abdominal distension (RR=0.49, 95% CI: 0.33–0.72), constipation (RR=0.38, 95% CI: 0.26–0.57), and nausea (RR=0.50, 95% CI: 0.37–0.68). However, it did not reduce the occurrence of abdominal pain, vomiting, or taste disorders.

Conclusions

S. boulardii supplementation in traditional eradication therapy significantly improves the H. pylori eradication rate and reduces the total adverse effects and incidence of diarrhea, bloating, constipation, and nausea.

Systematic review registration

Prospero, identifier CRD42024549780.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Helicobacter InfectionsHelicobacter pyloriProbioticsSaccharomyces boulardiiHumansAnti-Bacterial AgentsProton Pump InhibitorsTreatment Outcome

Stichwörter der Autor:innen

Helicobacter pyloriSaccharomyces boulardiiadverse effectseradication ratemeta-analysis

Substanzen

Anti-Bacterial AgentsProton Pump Inhibitors

Autor:innen und Institutionen

  • Department of Gastroenterology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.

Zitieren

APA

Li, M., & Xie, Y. (2025). Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradication of Helicobacter pylori: a meta-analysis. Frontiers in Cellular and Infection Microbiology, 15. https://doi.org/10.3389/fcimb.2025.1441185

Vancouver

Li M, Xie Y. Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradication of Helicobacter pylori: a meta-analysis. Frontiers in Cellular and Infection Microbiology. 2025;15. doi:10.3389/fcimb.2025.1441185

BibTeX
@article{Li2025,
  author = {Li, Manning and Xie, Ying},
  title = {Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradication of Helicobacter pylori: a meta-analysis},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2025},
  volume = {15},
  doi = {10.3389/fcimb.2025.1441185}
}
Kostenlos starten →